文献速递泌尿男性生殖肿瘤

HIF-2调控PTHrP与透明细胞肾癌副肿瘤性高钙血症

HIF-2-Dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear-Cell Renal Cell Carcinoma.
PubMed 文献 · Cancer Discov · 2025-01-01

研究利用肾细胞癌(RCC)肿瘤移植模型(TG)探讨HIF-2在副肿瘤性高钙血症(HC)中的作用。HIF-2抑制剂PT2399常使血钙正常化、降低循环PTHrP并减少HIF-2与PTHLH启动子结合;患者HC与透明细胞(cc)RCC相关,且可被PT2977/belzutifan快速纠正并下调PTHrP。

要点

  • HIF-2通过转录激活PTHLH驱动ccRCC副肿瘤性高钙血症。
  • HC和PTHrP可能作为HIF-2 engaged的预测生物标志物。
  • belzutifan可快速纠正HC并下调PTHrP,与双膦酸盐不同。

核心结论

  • HIF-2直接转录激活PTHLH(编码PTHrP),驱动ccRCC副肿瘤性高钙血症,支持评估HIF-2拮抗剂治疗此类患者。

研究设计与样本

  • 利用RCC肿瘤移植(TG)模型研究HC,模型以肿瘤细胞自主性炎症和免疫特征为特点。
  • 患者层面分析副肿瘤性HC与ccRCC及肉瘤样或横纹肌样分化的关联。

主要发现

  • PT2399抑制HIF-2常使血钙正常化、下调循环PTHrP并减少HIF-2与PTHLH启动子结合。
  • PTHLH位点在TG(HC)中整体更可及,但PT2399对PTHLH染色质可及性无明显影响(不同于EPO位点)。
  • 患者副肿瘤性HC与ccRCC(及肉瘤样或横纹肌样分化)相关,PT2977/belzutifan可快速纠正并下调PTHrP。

临床怎么用

  • 对ccRCC伴副肿瘤性高钙血症患者,可考虑评估HIF-2拮抗剂(如belzutifan)以纠正高钙并下调PTHrP。

局限性

  • 研究主要基于RCC肿瘤移植模型,患者数据为关联性观察,需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Patients with renal cell carcinoma (RCC) and hypercalcemia (HC) have worse outcomes. HC often involves parathyroid hormone-related protein (PTHrP), and the role of hypoxia-inducible factor 2 (HIF-2) is incompletely understood. Leveraging RCC tumorgraft (TG) models of HC, which were characterized by tumor cell-autonomous inflammatory/immune signatures, we show that HIF-2 inhibition with PT2399 frequently normalized calcium, downregulated circulating PTHrP, and reduced HIF-2 binding to the PTHLH (PTHrP) promoter. Likely contributing to the selective induction of PTHrP in a subset of HIF-2-dependent tumors, the PTHLH locus was generally more accessible in TG(HC). However, PTHLH chromatin accessibility was grossly unaffected by PT2399, unlike elsewhere (including the EPO locus in a TG with paraneoplastic polycythemia). As in TGs, paraneoplastic HC in patients was associated with clear-cell (cc)RCC (and sarcomatoid/rhabdoid differentiation) and was rapidly corrected by PT2977/belzutifan, which unlike bisphosphonates downregulated PTHrP. Our data support evaluating HIF-2 antagonists for ccRCC patients with paraneoplastic HC, which may serve as a predictive biomarker. SIGNIFICANCE: This study uncovers a direct role for HIF-2 in driving humoral HC of malignancy in ccRCC through transcriptional activation of PTHLH (encoding PTHrP), identifies HC (and PTHrP) as potentially predictive biomarkers of HIF-2 engagement, and sets a foundation for the evaluation of HIF-2 antagonists for HC management in patients.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Mal A, Xie B, Gray Z, et al. HIF-2-Dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2025. PMID: 41065553. doi:10.1158/2159-8290.CD-25-0638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。